EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients

Eirik Aaseth, Jon R Christiansen

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14645 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Eirik Aaseth und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Innlandet Hospital Trust, Elverum, Norway. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Cardiomyopathies, Heart Diseases, Heart Failure. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Department of Nuclear Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by increased wall thickness, diastolic dysfunction and progressive heart failure symptoms. The disease may infiltrate the conduction system leading to conduction disturbances requiring an implantation of permanent cardiac pacemaker (PM), but the extent is unknown. Here, we report the prevalence of ATTR-CM in patients ≥65 years with PM. Methods and results In this prospective, cross-sectional single-centre study patients were recruited from our out-patient pacemaker clinic. Eligibility criteria were age above 65 years, permanent cardiac pacemaker and competent to give informed consent. Patients underwent echocardiography at the pacemaker visit and were referred to 99mTc-DPD-scintigraphy (DPD) and blood samples if septum thickness was ≥12 mm, defined as left ventricular hypertrophy (LVH). Fifty eight of the 128 patients had LVH on echocardiography. Eleven patients had a DPD-scintigraphy based diagnosis of ATTR-CM, which represent 19% of patients with LVH and 9% of the total cohort. Patients diagnosed with ATTR-CM had higher concentrations of cardiac biomarkers (P < 0.001), higher E/E′ (P = 0.001), and lower global longitudinal strain (P = 0.003) on echocardiography and more heart failure symptoms (P = 0.001).

Conclusions

The prevalence of ATTR-CM in elderly patients with PM and LVH on echocardiography was 19%.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyloid Neuropathies, FamilialCardiomyopathiesHeart DiseasesHeart FailurePacemaker, ArtificialHumansAgedPrealbuminProspective StudiesPrevalenceCross-Sectional StudiesHypertrophy, Left Ventricular

Stichwörter der Autor:innen

Cardiac amyloidosisLeft ventricular hypertrophyPermanent cardiac pacemakerTransthyretin amyloid cardiomyopathy

Substanzen

Prealbumin

Autor:innen und Institutionen

  • Department of Medicine, Innlandet Hospital Trust, Elverum, Norway.
  • Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway.

Förderung

  • Department of Nuclear Medicine

Zitieren

APA

Aaseth, E., & Christiansen, J. R. (2024). Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients. ESC Heart Failure. https://doi.org/10.1002/ehf2.14645

Vancouver

Aaseth E, Christiansen JR. Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients. ESC Heart Failure. 2024. doi:10.1002/ehf2.14645

BibTeX
@article{Aaseth2024,
  author = {Aaseth, Eirik and Christiansen, Jon R},
  title = {Prevalence of Transthyretin Amyloid Cardiomyopathy in Pacemaker Patients},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14645}
}
Kostenlos starten →